News in SummaryCloud DX insiders (as defined by the TSX Venture Exchange) holding approximately 33% of the issued and outstanding…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing…
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis…
MARKHAM, Ontario, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has…
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as…
CLC invites individual and institutional investors, as well as advisors and analysts, to attend our interactive presentation real-time on VirtualInvestorConferences.comVANCOUVER,…
VICTORIA, British Columbia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Vigil Health Solutions Inc. (“Vigil” or the “Company”) (TSXV: VGL) announced…
CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines…
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on…
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as…